Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices -United States, 2024–2025.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      COVID-19 vaccines; VACCINE effectiveness; UNITED States. Advisory Committee on Immunization Practices; UNITED States. Food & Drug Administration; NOVAVAX Inc.; EMERGENCY use authorization
    • Abstract:
      COVID-19 vaccination provides additional protection against severe COVID-19–associated illness and death. Since September 2023, 2023–2024 Formula monovalent XBB.1-strain COVID-19 vaccines have been recommended for use in the United States for all persons aged ≥6 months. However, SARS-CoV-2 continues to evolve, and since winter 2023–2024, Omicron JN.1 lineage strains of SARS-CoV-2, including the JN.1 strain and the KP.2 strain, have been widely circulating in the United States. Further, COVID-19 vaccine effectiveness is known to wane. On June 27, 2024, the Advisory Committee on Immunization Practices (ACIP) recommended 2024–2025 COVID-19 vaccination with a Food and Drug Administration (FDA)–approved or authorized vaccine for all persons aged ≥6 months. On August 22, 2024, FDA approved the 2024–2025 COVID-19 vaccines by Moderna and Pfizer-BioNTech (based on the KP.2 strain) for use in persons aged ≥12 years and authorized these vaccines for use in children aged 6 months–11 years under Emergency Use Authorization (EUA). On August 30, 2024, FDA authorized 2024–2025 COVID-19 vaccine by Novavax (based on the JN.1 strain) for use in persons aged ≥12 years under EUA. ACIP will continue to evaluate new evidence as it becomes available and will update recommendations as needed. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of MMWR: Morbidity & Mortality Weekly Report is the property of Centers for Disease Control & Prevention (CDC) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)